<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Retinitis Pigmentosa - Inherited Retinal Degeneration Guide | Vision Health Portal</title>
    <meta name="description"
        content="Comprehensive guide to retinitis Pigmentosa: inherited retinal degeneration, night blindness, tunnel vision, bone spicule pigment, ERG testing, gene therapy, and vitamin A treatment.">
    <link rel="stylesheet" href="../style.css">
    <link rel="stylesheet" href="disease-style.css">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/6.0.0/css/all.min.css">
</head>

<body>
    <header>
        <a href="../index.html" class="logo">
            <i class="fas fa-eye"></i> VisionHealth
        </a>
        <nav>
            <ul>
                <li><a href="../index.html">Home</a></li>
                <li><a href="../tests/index.html">Vision Tests</a></li>
                <li><a href="../innovations.html">Innovations</a></li>
            </ul>
        </nav>
    </header>

    <div class="disease-hero">
        <h1>Retinitis Pigmentosa (RP)</h1>
        <p>Inherited Progressive Retinal Degeneration</p>
        <span class="category"><i class="fas fa-tag"></i> Retinal Disorder (Genetic)</span>
    </div>

    <div class="disease-content-wrapper">
        <aside class="toc">
            <h3>Contents</h3>
            <ul>
                <li><a href="#overview">Overview</a></li>
                <li><a href="#genetics">Genetics & Inheritance</a></li>
                <li><a href="#causes">Causes</a></li>
                <li><a href="#symptoms">Symptoms & Progression</a></li>
                <li><a href="#diagnosis">Diagnosis</a></li>
                <li><a href="#complications">Complications</a></li>
                <li><a href="#treatment">Treatment & Management</a></li>
                <li><a href="#research">Research & Future Therapies</a></li>
                <li><a href="#living">Living with RP</a></li>
                <li><a href="#when-to-see">When to See a Doctor</a></li>
            </ul>
        </aside>

        <main class="disease-content">
            <section id="overview">
                <h2>What Is Retinitis Pigmentosa?</h2>
                <p>Retinitis Pigmentosa (RP) is a group of rare, inherited eye diseases that cause progressive
                    degeneration of the photoreceptor cells (rods and cones) in the retina. The retina is the
                    light-sensitive tissue lining the back of the eye responsible for converting visual images into
                    nerve signals sent to the brain. In RP, the photoreceptors gradually die, leading to progressive
                    vision loss that typically begins with night blindness and peripheral (side) vision loss, eventually
                    progressing to tunnel vision and, in some cases, near-total blindness.</p>

                <p>The term "retinitis pigmentosa" is somewhat misleading—it's not an inflammatory condition
                    ("retinitis" suggests inflammation), but rather a genetic dystrophy. The "pigmentosa" refers to the
                    characteristic appearance of dark pigment deposits ("bone spicules") visible in the retina during
                    examination. RP affects approximately 1 in 4,000 people worldwide, with symptoms typically appearing
                    in childhood or adolescence, though onset and progression vary widely among individuals and
                    depending on the specific genetic mutation involved.</p>

                <div class="key-facts">
                    <h3><i class="fas fa-info-circle"></i> Key Facts About Retinitis Pigmentosa</h3>
                    <ul>
                        <li><strong>Inherited disease:</strong> Caused by genetic mutations affecting photoreceptor
                            function and survival.</li>
                        <li><strong>Progressive vision loss:</strong> Worsens over time; rate varies widely.</li>
                        <li><strong>Night blindness first:</strong> Difficulty seeing in dim light typically earliest
                            symptom.</li>
                        <li><strong>Tunnel vision:</strong> Loss of peripheral vision; central vision often preserved
                            longer.</li>
                        <li><strong>Bone spicule pigment:</strong> Characteristic pigment deposits visible on retinal
                            exam.</li>
                        <li><strong>No cure (yet):</strong> Treatments can slow progression but cannot currently restore
                            lost vision (gene therapy emerging).</li>
                        <li><strong>Variable prognosis:</strong> Some retain useful vision throughout life; others
                            become legally blind by midlife.</li>
                        <li><strong>Multiple inheritance patterns:</strong> Autosomal dominant, autosomal recessive, or
                            X-linked.</li>
                    </ul>
                </div>

                <p>Understanding RP is critical for early diagnosis, genetic counseling, access to low vision services,
                    and participating in emerging clinical trials.</p>
            </section>

            <section id="genetics">
                <h2>Genetics and Inheritance</h2>

                <h3>Genetic Basis</h3>
                <ul>
                    <li>RP is caused by mutations in over <strong>100 different genes</strong></li>
                    <li>These genes are involved in photoreceptor structure, function, and survival</li>
                    <li>Different mutations cause different rates of progression and severity</li>
                </ul>

                <h3>Inheritance Patterns</h3>

                <h4>Autosomal Dominant RP (~30-40% of cases)</h4>
                <ul>
                    <li>One copy of mutated gene (from one parent) causes disease</li>
                    <li>50% chance of passing to each child</li>
                    <li>Both males and females equally affected</li>
                    <li>Often milder, later onset</li>
                    <li>Common genes: RHO (rhodopsin), PRPH2 (peripherin-2)</li>
                </ul>

                <h4>Autosomal Recessive RP (~50-60% of cases)</h4>
                <ul>
                    <li>Two copies of mutated gene (one from each parent) needed</li>
                    <li>Parents usually carriers (unaffected)</li>
                    <li>25% chance affected child if both parents carriers</li>
                    <li>Both males and females equally affected</li>
                    <li>Often earlier onset, more severe</li>
                    <li>Common genes: USH2A, EYS, PDE6A, PDE6B</li>
                </ul>

                <h4>X-Linked RP (~10-20% of cases)</h4>
                <ul>
                    <li>Mutation on X chromosome</li>
                    <li>Primarily affects males (one X chromosome)</li>
                    <li>Females usually carriers with mild or no symptoms</li>
                    <li>Mother passes to 50% of sons (affected) and 50% of daughters (carriers)</li>
                    <li>Often most severe form</li>
                    <li>Common gene: RPGR</li>
                </ul>

                <h4>Simplex/Sporadic Cases (~20-40%)</h4>
                <ul>
                    <li>No family history</li>
                    <li>New mutation or recessive inheritance with carrier parents</li>
                </ul>

                <h3>Genetic Testing</h3>
                <ul>
                    <li>Identifies specific mutation in many cases</li>
                    <li>Aids prognosis, genetic counseling</li>
                    <li>Essential for enrollment in mutation-specific clinical trials</li>
                    <li>Commercially available multi-gene panels</li>
                </ul>
            </section>

            <section id="causes">
                <h2>What Causes RP?</h2>

                <h3>Photoreceptor Degeneration</h3>
                <p>Mechanism of vision loss:</p>
                <ul>
                    <li><strong>Rods affected first:</strong>
                        <ul>
                            <li>Rods responsible for peripheral and night vision</li>
                            <li>Degenerate and die off progressively</li>
                            <li>Causes night blindness and peripheral vision loss</li>
                        </ul>
                    </li>
                    <li><strong>Cones affected later:</strong>
                        <ul>
                            <li>Cones responsible for central, color, and detailed vision</li>
                            <li>Eventually degenerate in many patients</li>
                            <li>Causes central vision loss</li>
                        </ul>
                    </li>
                </ul>

                <h3>Why Photoreceptors Die</h3>
                <p>Mutations affect:</p>
                <ul>
                    <li>Phototransduction (light-sensing process)</li>
                    <li>Photoreceptor structure and maintenance</li>
                    <li>Retinal pigment epithelium (RPE) support of photoreceptors</li>
                    <li>Metabolic pathways essential for cell survival</li>
                </ul>

                <h3>Secondary Changes</h3>
                <ul>
                    <li>Retinal blood vessels narrow (attenuated vessels)</li>
                    <li>Optic nerve becomes pale (atrophy)</li>
                    <li>Pigment deposits form ("bone spicules")</li>
                    <li>Retina thins</li>
                </ul>
            </section>

            <section id="symptoms">
                <h2>Symptoms and Disease Progression</h2>

                <div class="symptoms-grid">
                    <div class="symptom-card">
                        <h4><i class="fas fa-moon"></i> Night Blindness (Nyctalopia)</h4>
                        <p>Difficulty seeing in dim light or darkness; often first symptom, appearing in
                            childhood/adolescence.</p>
                    </div>

                    <div class="symptom-card">
                        <h4><i class="fas fa-compress-arrows-alt"></i> Loss of Peripheral Vision</h4>
                        <p>Gradual narrowing of visual field; "tunnel vision"; difficulty seeing to the sides while
                            walking.</p>
                    </div>

                    <div class="symptom-card">
                        <h4><i class="fas fa-adjust"></i> Difficulty with Contrast</h4>
                        <p>Trouble distinguishing objects from background; reading becomes harder.</p>
                    </div>

                    <div class="symptom-card">
                        <h4><i class="fas fa-sun"></i> Light Sensitivity (Photophobia)</h4>
                        <p>Glare sensitivity, especially in bright sunlight; may develop as cones affected.</p>
                    </div>

                    <div class="symptom-card">
                        <h4><i class="fas fa-palette"></i> Color Vision Changes</h4>
                        <p>Difficulty distinguishing colors, especially blues and greens, as cones degenerate.</p>
                    </div>

                    <div class="symptom-card">
                        <h4><i class="fas fa-eye-slash"></i> Central Vision Loss (Late)</h4>
                        <p>Reading and recognizing faces become difficult; occurs in advanced stages in many patients.
                        </p>
                    </div>
                </div>

                <h3>Typical Progression</h3>

                <h4>Early Stage (Childhood/Adolescence)</h4>
                <ul>
                    <li>Night blindness</li>
                    <li>Subtle peripheral vision loss</li>
                    <li>Difficulty adapting to dark</li>
                    <li>Tripping, bumping into objects not noticed peripherally</li>
                </ul>

                <h4>Middle Stage (20s-40s)</h4>
                <ul>
                    <li>Pronounced tunnel vision</li>
                    <li>Difficulty with mobility (may use cane)</li>
                    <li>Trouble driving (may lose license)</li>
                    <li>Reading still possible for many</li>
                </ul>

                <h4>Advanced Stage (40s-60s and beyond)</h4>
                <ul>
                    <li>Severe tunnel vision or only small central island remaining</li>
                    <li>Central vision may deteriorate</li>
                    <li>Legal blindness common (though complete blackness rare)</li>
                    <li>May retain light perception even if functionally blind</li>
                </ul>

                <h3>Rate of Progression</h3>
                <ul>
                    <li><strong>Highly variable</strong> depending on specific mutation and inheritance pattern</li>
                    <li>Some patients retain useful vision throughout life</li>
                    <li>Others lose most vision by age 40-50</li>
                    <li>X-linked RP often progresses fastest</li>
                    <li>Autosomal dominant often slowest</li>
                </ul>
            </section>

            <section id="diagnosis">
                <h2>Diagnosis</h2>

                <h3>Clinical History</h3>
                <ul>
                    <li>Night blindness, especially in childhood?</li>
                    <li>Difficulty with peripheral vision?</li>
                    <li>Family history of vision loss or RP?</li>
                    <li>Onset and progression</li>
                </ul>

                <h3>Comprehensive Eye Examination</h3>

                <h4>Visual Acuity</h4>
                <ul>
                    <li>May be normal or near-normal in early stages</li>
                    <li>Decreases as disease progresses</li>
                </ul>

                <h4>Fundus Examination (Dilated Retinal Exam)</h4>
                <p>Classic findings:</p>
                <ul>
                    <li><strong>Bone spicule pigmentation:</strong> Dark pigment deposits in mid-peripheral retina,
                        resembling bone spicules</li>
                    <li><strong>Attenuated retinal blood vessels:</strong> Narrowed, thin vessels</li>
                    <li><strong>Waxy pale optic disc:</strong> Optic nerve atrophy</li>
                    <li><strong>Macular changes:</strong> Later stages may show macular atrophy or cystoid macular edema
                    </li>
                </ul>

                <h4>Visual Field Testing (Perimetry)</h4>
                <ul>
                    <li>Quantifies peripheral vision loss</li>
                    <li>Shows progressive constriction over time</li>
                    <li>Classic "ring scotoma" (mid-peripheral blind spot) in some cases</li>
                    <li>Tracks disease progression</li>
                </ul>

                <h3>Electrophysiology Testing</h3>

                <h4>Electroretinogram (ERG) - Gold Standard</h4>
                <ul>
                    <li>Measures electrical responses of photoreceptors and retinal cells to light</li>
                    <li><strong>Key finding:</strong> Markedly reduced or absent responses</li>
                    <li>Detects disease even before visible symptoms</li>
                    <li>Differentiates RP from other retinal diseases</li>
                    <li>Rod and cone function assessed separately</li>
                </ul>

                <h3>Imaging</h3>

                <h4>Optical Coherence Tomography (OCT)</h4>
                <ul>
                    <li>High-resolution cross-sectional images of retina</li>
                    <li>Shows thinning of outer retinal layers (photoreceptors)</li>
                    <li>Detects cystoid macular edema (CME)</li>
                    <li>Monitors disease progression</li>
                </ul>

                <h4>Fundus Autofluorescence (FAF)</h4>
                <ul>
                    <li>Imaging technique showing RPE health</li>
                    <li>Patterns of autofluorescence correlate with disease severity</li>
                    <li>Useful research and monitoring tool</li>
                </ul>

                <h3>Genetic Testing</h3>
                <ul>
                    <li>Identifies specific gene mutation</li>
                    <li>Multi-gene panels test for hundreds of genes simultaneously</li>
                    <li>Confirms diagnosis, determines inheritance pattern</li>
                    <li>Critical for family planning and genetic counseling</li>
                    <li>Enables participation in gene-specific clinical trials</li>
                    <li>Success rate: ~50-70% (mutation identified)</li>
                </ul>

                <h3>Differential Diagnosis</h3>
                <p>Other conditions that can mimic RP:</p>
                <ul>
                    <li>Other inherited retinal dystrophies (e.g., cone-rod dystrophy, choroideremia)</li>
                    <li>Usher syndrome (RP + hearing loss)</li>
                    <li>Vitamin A deficiency</li>
                    <li>Medication toxicity (e.g., chloroquine/hydroxychloroquine)</li>
                    <li>Syphilis (rare cause of similar appearance)</li>
                </ul>
            </section>

            <section id="complications">
                <h2>Complications</h2>

                <h3>Cystoid Macular Edema (CME)</h3>
                <ul>
                    <li>Fluid accumulation in macula (central retina)</li>
                    <li>Occurs in ~20-30% of RP patients</li>
                    <li>Causes central vision blurring</li>
                    <li>Treatable with carbonic anhydrase inhibitors or steroids</li>
                    <li>Can be chronic or intermittent</li>
                </ul>

                <h3>Cataract</h3>
                <ul>
                    <li>Posterior subcapsular cataracts common</li>
                    <li>May develop earlier than typical aging cataracts</li>
                    <li>Exacerbates vision loss</li>
                    <li>Cataract surgery can improve vision if significant cataract present</li>
                </ul>

                <h3>Myopia (Nearsightedness)</h3>
                <ul>
                    <li>Associated with some RP types</li>
                    <li>Can progress</li>
                </ul>

                <h3>Glaucoma</h3>
                <ul>
                    <li>Slightly increased risk</li>
                    <li>Monitor eye pressure regularly</li>
                </ul>

                <h3>Psychological Impact</h3>
                <ul>
                    <li>Depression, anxiety common</li>
                    <li>Grief over vision loss</li>
                    <li>Social isolation</li>
                    <li>Career and lifestyle limitations</li>
                </ul>
            </section>

            <section id="treatment">
                <h2>Treatment and Management</h2>

                <div class="alert-box warning">
                    <h4><i class="fas fa-info-circle"></i> Current State of Treatment</h4>
                    <p>There is currently <strong>no cure</strong> for most forms of RP, and treatments that restore
                        lost vision are extremely limited. However, several approaches can slow progression, manage
                        complications, and improve quality of life. <strong>Gene therapy</strong> has recently become
                        available for one specific mutation, and research is advancing rapidly.</p>
                </div>

                <h3>Vitamin A Supplementation</h3>
                <ul>
                    <li>Based on clinical trial showing modest slowing of progression</li>
                    <li><strong>Dose:</strong> 15,000 IU/day vitamin A palmitate</li>
                    <li><strong>Slows decline:</strong> May delay progression by ~2 years on average</li>
                    <li><strong>Not for everyone:</strong> Consult doctor; not recommended for some RP subtypes (e.g.,
                        Usher syndrome type 2, certain mutations)</li>
                    <li><strong>Caution:</strong> Avoid in pregnancy (teratogenic at high doses)</li>
                    <li>Monitor liver function</li>
                </ul>

                <h3>DHA (Docosahexaenoic Acid) Supplementation</h3>
                <ul>
                    <li>Omega-3 fatty acid</li>
                    <li>Some evidence of slowing progression when combined with vitamin A</li>
                    <li>Dose: ~200-1,200 mg/day</li>
                </ul>

                <h3>Treatment of Cystoid Macular Edema (CME)</h3>
                <ul>
                    <li><strong>Oral carbonic anhydrase inhibitors:</strong> Acetazolamide or methazolamide; reduce
                        fluid</li>
                    <li><strong>Topical drops:</strong> Dorzolamide</li>
                    <li><strong>Steroids:</strong> Rarely used (eye injections or oral)</li>
                    <li>Can improve central vision if CME contributing to blur</li>
                </ul>

                <h3>Cataract Surgery</h3>
                <ul>
                    <li>If cataract develops and impairs remaining vision</li>
                    <li>Standard cataract surgery</li>
                    <li>Can improve vision quality significantly</li>
                </ul>

                <h3>Low Vision Aids and Rehabilitation</h3>
                <p>Critical for maintaining independence:</p>
                <ul>
                    <li><strong>Magnifiers:</strong> Handheld, stand, electronic video magnifiers for reading</li>
                    <li><strong>Large-print materials, audiobooks</strong></li>
                    <li><strong>Screen readers, text-to-speech software</strong></li>
                    <li><strong>Mobility training:</strong> Orientation and mobility specialists teach cane use,
                        navigation</li>
                    <li><strong>Lighting:</strong> Bright task lighting, avoid glare</li>
                    <li><strong>Contrast enhancement:</strong> High-contrast settings on devices</li>
                </ul>

                <h3>Protective Eyewear</h3>
                <ul>
                    <li>UV-blocking sunglasses</li>
                    <li>Some animal studies suggest UV may accelerate damage</li>
                    <li>Reduces glare sensitivity</li>
                </ul>

                <h3>Regular Monitoring</h3>
                <ul>
                    <li>Annual eye exams</li>
                    <li>Visual field testing to track progression</li>
                    <li>OCT for CME surveillance</li>
                    <li>Genetic counseling for family planning</li>
                </ul>
            </section>

            <section id="research">
                <h2>Research and Emerging Therapies</h2>

                <h3>Gene Therapy - Breakthrough Treatment</h3>

                <h4>Luxturna (Voretigene Neparvovec) - FDA Approved 2017</h4>
                <ul>
                    <li><strong>First FDA-approved gene therapy for inherited retinal disease</strong></li>
                    <li><strong>For:</strong> Biallelic RPE65 mutations (rare form of RP)</li>
                    <li><strong>Mechanism:</strong> Delivers working copy of RPE65 gene to retinal cells via viral
                        vector</li>
                    <li><strong>Procedure:</strong> Subretinal injection surgery</li>
                    <li><strong>Results:</strong> Improved vision, light sensitivity in many patients</li>
                    <li><strong>Limitation:</strong> Only for specific mutation (~1-2% of RP cases)</li>
                    <li><strong>Cost:</strong> Extremely expensive (~$850,000 for both eyes)</li>
                </ul>

                <h4>Other Gene Therapies in Clinical Trials</h4>
                <ul>
                    <li>Trials ongoing for other mutations (RPGR, RHO, PDE6B, others)</li>
                    <li>CRISPR gene editing being explored</li>
                </ul>

                <h3>Retinal Implants (Bionic Eye)</h3>
                <ul>
                    <li><strong>Argus II:</strong> Electronic retinal prosthesis; provides rudimentary vision
                        (light/dark, shapes) in profound blindness</li>
                    <li>Requires surgery to implant electrode array on retina</li>
                    <li>Limited vision restoration but can aid navigation</li>
                    <li>Company discontinued product; newer systems in development</li>
                </ul>

                <h3>Stem Cell Therapy</h3>
                <ul>
                    <li>Replacing dead photoreceptors with stem cell-derived cells</li>
                    <li>In early clinical trial stages</li>
                    <li>Promising but years away from widespread use</li>
                </ul>

                <h3>Optogenetics</h3>
                <ul>
                    <li>Genetically modifying surviving retinal cells to become light-sensitive (replacing dead
                        photoreceptors' function)</li>
                    <li>Early clinical trials</li>
                    <li>Partial vision restoration reported in some cases</li>
                </ul>

                <h3>Neuroprotective Therapies</h3>
                <ul>
                    <li>Medications to slow photoreceptor death</li>
                    <li>Various trials ongoing (e.g., ciliary neurotrophic factor implants)</li>
                </ul>

                <h3>Participation in Clinical Trials</h3>
                <ul>
                    <li>Genetic testing essential to match patients to mutation-specific trials</li>
                    <li>ClinicalTrials.gov lists ongoing studies</li>
                    <li>Foundation Fighting Blindness (FFB) maintains trial database</li>
                </ul>
            </section>

            <section id="living">
                <h2>Living with Retinitis Pigmentosa</h2>

                <h3>Mobility and Safety</h3>
                <ul>
                    <li><strong>Orientation and mobility training:</strong> Learn cane techniques, safe navigation</li>
                    <li><strong>Home modifications:</strong> Bright lighting, remove tripping hazards, high-contrast
                        markings</li>
                    <li><strong>Guide dog:</strong> For some patients</li>
                    <li><strong>GPS and smartphone apps:</strong> Navigation aids</li>
                </ul>

                <h3>Employment and Education</h3>
                <ul>
                    <li>Vocational rehabilitation services</li>
                    <li>Assistive technology (screen readers, magnification software)</li>
                    <li>Career counseling toward accessible fields</li>
                    <li>Educational accommodations (extra time, audio textbooks)</li>
                </ul>

                <h3>Driving</h3>
                <ul>
                    <li>Most eventually unable to drive due to peripheral vision loss</li>
                    <li>License depends on meeting visual field/acuity requirements</li>
                    <li>Plan for alternative transportation</li>
                </ul>

                <h3>Psychological Support</h3>
                <ul>
                    <li>Counseling for coping with progressive vision loss</li>
                    <li>Support groups (Foundation Fighting Blindness, local groups)</li>
                    <li>Peer support from others with RP</li>
                </ul>

                <h3>Family Planning and Genetic Counseling</h3>
                <ul>
                    <li>Discuss inheritance risk with genetic counselor</li>
                    <li>Carrier testing for at-risk relatives</li>
                    <li>Prenatal or preimplantation genetic diagnosis options</li>
                </ul>
            </section>

            <section id="when-to-see">
                <h2>When to See a Doctor</h2>

                <div class="alert-box warning">
                    <h4><i class="fas fa-exclamation-triangle"></i> Seek Evaluation If:</h4>
                    <ul>
                        <li><strong>Night blindness,</strong> especially if developing in childhood/adolescence</li>
                        <li><strong>Difficulty seeing peripherally or frequent tripping</strong></li>
                        <li><strong>Family history of RP or vision loss</strong></li>
                        <li><strong>Progressive vision changes</strong></li>
                    </ul>
                    <p>Early diagnosis allows for genetic testing, counseling, enrollment in trials, and planning for
                        low vision needs.</p>
                </div>

                <h3>Regular Follow-Up If Diagnosed</h3>
                <ul>
                    <li>Annual comprehensive eye exams</li>
                    <li>Visual field testing to monitor progression</li>
                    <li>OCT to check for CME</li>
                    <li>Consider genetic testing if not done</li>
                    <li>Stay informed about clinical trials</li>
                </ul>

                <h3>Questions to Ask Your Doctor</h3>
                <ul>
                    <li>What type/mutation of RP do I have?</li>
                    <li>Should I get genetic testing?</li>
                    <li>What is my prognosis?</li>
                    <li>Should I take vitamin A or DHA supplements?</li>
                    <li>Am I eligible for any clinical trials?</li>
                    <li>When should I access low vision services?</li>
                    <li>What are the implications for my children/family?</li>
                </ul>
            </section>

            <div class="alert-box info">
                <h4><i class="fas fa-lightbulb"></i> Bottom Line</h4>
                <p>Retinitis Pigmentosa is a group of inherited retinal diseases causing progressive degeneration of
                    photoreceptor cells, leading to night blindness, tunnel vision, and potential severe vision loss.
                    Caused by mutations in over 100 genes, RP can follow autosomal dominant, recessive, or X-linked
                    inheritance. While there's currently no cure for most forms, vitamin A supplementation may modestly
                    slow progression, and low vision aids significantly improve quality of life. Exciting developments
                    are emerging: gene therapy (Luxturna) is now available for one specific RP mutation, and numerous
                    clinical trials are underway for other mutations. Genetic testing is crucial for diagnosis,
                    prognosis, family counseling, and trial eligibility. If you or your child experience night blindness
                    or peripheral vision loss, seek evaluation—early diagnosis enables access to emerging therapies and
                    support services.</p>
            </div>

            <div class="related-diseases">
                <h3>Related Eye Conditions</h3>
                <div class="related-links">
                    <a href="macular-degeneration.html">Macular Degeneration</a>
                    <a href="diabetic-retinopathy.html">Diabetic Retinopathy</a>
                    <a href="retinal-detachment.html">Retinal Detachment</a>
                    <a href="usher-syndrome.html">Usher Syndrome</a>
                </div>
            </div>
        </main>
    </div>

    <footer>
        <div class="footer-content">
            <p>&copy; 2025 Vision Health Portal. All rights reserved.</p>
            <p class="designer-credit">Designed by RITIK DHAGE</p>
            <p style="font-size: 0.85rem; margin-top: 1rem; opacity: 0.8;">
                <i class="fas fa-info-circle"></i> This information is for educational purposes only and is not a
                substitute for professional medical advice, diagnosis, or treatment.
            </p>
        </div>
    </footer>
</body>

</html>